Subtype
Prostate Neoplasm
CI-CAN-00003778Explore in graph →
Non-malignant1,453 active trials24 approved drugs58 evidence items
Loading cancer entity…
Subtype
CI-CAN-00003778Explore in graph →
Clinical trials
6,544 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00421694 | Positive Surgical Margins Rate and EGFR Family Members Expression in Prostate Cancer Treated With Bicalutamide | completed | Phase 2 / Phase 3 | 119 | University of L'AquilaOTHER | 1 | Oct 8, 2007 | clinicaltrials |
| NCT00115635 | Docetaxel and Gemcitabine in Hormonal Refractory Metastatic Prostate Cancer | completed | Phase 1 / Phase 2 | 60 | Herlev HospitalOTHER | 1 | Oct 2, 2007 | clinicaltrials |
| NCT00070837 |
| MLN2704 in Subjects With Metastatic Androgen-Independent Prostate Cancer |
| completed |
| Phase 1 / Phase 2 |
| 46 |
| Millennium Pharmaceuticals, Inc.INDUSTRY |
| 1 |
| Jul 13, 2007 |
| clinicaltrials |
| NCT00200187 | A Randomized Study of the Efficacy of Low Venous Pressure General Anesthesia Versus Combined Spinal-Epidural Anesthesia in Decreasing Blood Loss During Prostate Surgery | completed | Phase 2 | 246 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 26, 2007 | clinicaltrials |
| NCT00040586 | Phase II Trial of Monoclonal Antibody (J591) in Combination With Low-Dose Subcutaneous Interleukin-2 | completed | Phase 2 | — | BZL BiologicsINDUSTRY | 1 | Jan 22, 2007 | clinicaltrials |
| NCT00072722 | Safety and Efficacy of CC-4047 in Subjects With Metastatic Hormone Refractory Prostate Cancer (HRPC) | completed | Phase 2 | 36 | Celgene CorporationINDUSTRY | 1 | Dec 19, 2006 | clinicaltrials |
| NCT00100243 | Study of Abarelix in Androgen-Independent Prostate Cancer Progressing After Agonist Therapy | completed | Phase 2 | 22 | PRAECIS Pharmaceuticals Inc.INDUSTRY | 1 | Sep 19, 2006 | clinicaltrials |
| NCT00039793 | Massage Therapy for Cancer-Related Fatigue | completed | Phase 2 | 45 | National Center for Complementary and Integrative Health (NCCIH)NIH | 1 | Aug 18, 2006 | clinicaltrials |
| NCT00038662 | Safety and Efficacy of Atrasentan in Men With Hormone Naive Prostate Cancer Exhibiting Early Signs of Biochemical Failure | completed | Phase 2 | 200 | AbbottINDUSTRY | 2 | Aug 15, 2006 | clinicaltrials |
| NCT00164437 | CD-ROM Intervention for Prostate Cancer Screening | completed | Phase 2 / Phase 3 | 554 | Centers for Disease Control and PreventionFED | 1 | Sep 14, 2005 | clinicaltrials |
| NCT00140374 | Vaccination Priming and Vaccine Boosting Trial of Allogeneic Human GM-CSF Gene Transduced Irradiated Prostate Cancer Cell Vaccines (GVAX® Vaccine for Prostate Cancer) | completed | Phase 1 / Phase 2 | 36 | Cell GenesysINDUSTRY | 0 | Sep 1, 2005 | clinicaltrials |
| NCT00140387 | Prime-Boost Dose Scheduling Trial for Human GM-CSF Gene Transduced Irradiated Prostate Allogeneic Cancer Cell Vaccines (Allogeneic Prostate GVAX®) | completed | Phase 1 / Phase 2 | 20 | Cell GenesysINDUSTRY | 0 | Sep 1, 2005 | clinicaltrials |
| NCT00140400 | Prime-Boost Dose Scheduling Trial for Human GM-CSF Gene Transduced Irradiated Prostate Allogeneic Cancer Vaccine (Allogeneic Prostate GVAX®) in Patients With Hormone-Refractory Prostate Cancer | completed | Phase 1 / Phase 2 | 50 | Cell GenesysINDUSTRY | 0 | Sep 1, 2005 | clinicaltrials |
| NCT00116155 | Trial of IV Injection of CV787 in Hormone Refractory Metastatic Prostate Cancer | completed | Phase 1 / Phase 2 | — | Cell GenesysINDUSTRY | 0 | Jun 28, 2005 | clinicaltrials |
| NCT00061126 | ABX-EGF (a Monoclonal Antibody) Given to Patients With Prostate Cancer With or Without Tumor in Other Parts of the Body | completed | Phase 2 | 50 | AbgenixINDUSTRY | 1 | Jun 24, 2005 | clinicaltrials |
Data updated 22 days agoSource updated Oct 8, 2007source: clinicaltrials